Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Latest from Vanderbilt-Ingram Cancer Center

Dr Rini on Retreatment With Immunotherapy Following Progression in RCC

April 11th 2023

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Adding Patient-Specific Comorbidities May Improve Risk Evaluation in Myelofibrosis

ByJason Harris

April 11th 2023

Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.

Colorectal Cancer: An Overview on Molecular Profiling

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 7th 2023

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 7th 2023

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

Metastatic Colorectal Cancer: Future Directions in Care

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

April 3rd 2023

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 27th 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

Combination IO/TKI Strategies in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 27th 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

ByJennifer R. Green, MD

March 22nd 2023

Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.

Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 20th 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Overview of Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 20th 2023

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

Investigators Struggle to Understand Causes Behind Growth of Appendix Cancer

ByJason Harris

March 16th 2023

Investigators are unclear about the factors driving the explosive growth in incidence of appendiceal cancer over the past 2 decades.

Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 13th 2023

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 13th 2023

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 6th 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

Importance of Identifying HER2 Status in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 6th 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

Role of Tucatinib in HER2+ mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 27th 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 27th 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Investigational Treatments for Refractory RCC Expand Beyond Immunotherapy

ByAshling Wahner

February 23rd 2023

Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.

Trastuzumab Deruxtecan in HER2+ mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 20th 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

First-Line Treatment Options for mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 20th 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

Challenges With Molecular Testing in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Dr. Rini on the Current Standard of Care in R/R RCC

ByBrian I. Rini, MD

February 14th 2023

Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.

Tae Kon Kim, MD, PhD, assistant professor of medicine, Division of Hematology and Oncology, assistant professor of pathology, microbiology and immunology, Department of Pathology, Microbiology and Immunology, Vanderbilt Ingram Medical Center

Dr. Kim on the Synergistic Effect of PD-1H Blockade in AML

ByTae Kon Kim, MD, PhD

February 13th 2023

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Pashtoon M. Kasi, MBBS, MD, MS,Kanwal Raghav, MD,Joel R. Hecht, MD

February 9th 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.